Shots:

• Celenex (a Nationwide Children Hospital spin out) to receive an upfront of $100M cash- development milestones up to $15M- and may be eligible for up to $75M tiered sales ($500M /$750M) milestone payments with no royalties- $262M for BLA/MAA submission and approval milestones across multiple programs
• Amicus will not pay >$75M over the next 4 years in these milestones. The acquisition and related development costs of the programs will be funded by Biopharma Credit PLC providing $150M debt facility
• The lead programs in CLN6- CLN3- and CLN8 for Batten disease will support AAV vector developed by Nationwide Children Hospital in CNS genetic disease

Ref: Amicus Therapeutics | Image: Reuters